en

PRODUCT DETAIL

TAKHZYRO 300 mg injekčný roztok

Code 9987C
MA number EU/1/18/1340/001
Product Form: sol inj 1x2 ml/300 mg (liek.inj.skl.)
MA Status: E - Valid centralised marketing authorisation
Type of procedure: EU Orphan
MAH, country: Takeda Pharmaceuticals International AG Ireland Branch, Ireland
Therapeutic Class: 87 - VARIA I
ATC:
B BLOOD AND BLOOD FORMING ORGANS
B06 OTHER HEMATOLOGICAL AGENTS
B06A OTHER HEMATOLOGICAL AGENTS
B06AC Drugs used in hereditary angioedema
B06AC05 Lanadelumab
Shelf life: 24
Route of admin.: Subcutaneous use
Prescription Status: Medicinal product subject to restricted medical prescription.
Legal basis: Article 8(3) application - new active substance
MA issued: 22.11.2018
SmPC + PL: European Medicines Agency's database
Safety feature Yes
Data update: 30.08.2023
eu-flag.png sk-flag.png